I was skeptical. I've watched the hype cycles come and go in this field for long enough to be cautious about anything that gets called a miracle. Here's what changed my mind — and what I think every patient deserves to know about how this drug actually works.
I've never been a one-size-fits-all practitioner when it comes to weight loss. Weight loss, like anything else in nutrition and medicine, is very individualized — and I've seen what happens when we pretend otherwise. Patients get handed a protocol that worked for someone else, it doesn't work for them, and they walk away convinced the problem is with their willpower rather than with the approach.
My toolkit has always reflected that. I've used the CleanUP Metabolic Cleanse, the ProLon fasting mimicking diet, MIC injections with B12. I've worked with hormonal imbalance and insulin resistance as root causes rather than outcomes. For some patients, that combination gets them where they need to go. For others, there's a missing piece — and for a while I wasn't sure what it was.
I've also been cautious about stimulant-based approaches. Phentermine and its relatives can produce results in the short term, but the long-term metabolic picture concerns me. You're borrowing against your body's stress response, and that debt has a way of coming due. When I saw the semaglutide wave building, my first instinct was to file it in the same category: pharmaceutical quick fix, mechanism unclear, long-term picture unknown.
This is what I know now — not what the marketing materials say, but what the pharmacology actually shows and what I've watched happen in my practice.
Semaglutide is an injectable peptide — which means it's a building block of protein. It's sold under the brand names Ozempic and Wegovy, depending on the formulation and the indication being treated. The FDA approved it for type 2 diabetes management in 2017, and more recently for weight loss in patients without a diabetes diagnosis.
The mechanism is worth understanding, because it's what separates semaglutide from the stimulant-based weight loss approaches that I've been reluctant to use. This drug doesn't work by revving up your metabolism or suppressing appetite through adrenergic pathways. It works by mimicking a hormone your body already produces.
Semaglutide is a GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide 1 — a hormone produced naturally in your gut in response to eating. Its job, in the body's native version, is to regulate energy use and fat storage, signal satiety to the brain, and help manage blood sugar after meals. Semaglutide mimics that signal — at a stronger, more sustained level than your body would produce on its own.
This is not pharmacological coercion. It's amplification of a system that already exists. That's a meaningfully different category of intervention.
None of these are opinions. This is what the pharmacology shows.
GLP-1 receptor activation at the level of the hypothalamus — the brain's metabolic control center — shifts the body's energy equation. It promotes the use of stored fat as fuel and reduces the hormonal signaling that tells the body to hold onto adipose tissue. This is a metabolic shift, not just appetite suppression.
Semaglutide stimulates insulin release in response to food — but only when blood glucose is actually elevated. This glucose-dependent action is one of the reasons the drug has such a favorable safety profile compared to older diabetes medications. It also means patients with insulin resistance get meaningful glycemic benefit without the hypoglycemia risk that comes with other approaches.
The stomach empties more slowly when GLP-1 receptors are activated. This has a real physiological effect on appetite — food stays in the stomach longer, the feeling of fullness persists longer, and the glucose load reaching the bloodstream arrives more gradually. Patients describe this as not thinking about food the way they used to, which for many is a genuinely unfamiliar experience.
GLP-1 receptors in the hypothalamus and brainstem process hunger signals. When those receptors are activated by semaglutide, appetite decreases and the sense of satiety after meals increases. This is not the jittery appetite suppression of stimulant medications. Patients describe it as a quieting of the constant background noise around food — the cravings and the drive to eat beyond fullness simply become less urgent.
The weight loss is real and clinically significant. But the patients who have surprised me most are the ones who come back talking about things that aren't on the scale. The list of secondary benefits is not small — and the mechanisms behind them are increasingly well understood.
This one has surprised patients consistently, and it's worth explaining. Research has shown that a meaningful number of patients on semaglutide report a reduced desire to drink alcohol — not a deliberate reduction, but a kind of indifference that wasn't there before. They're not consciously resisting the urge. The urge is simply less present.
The mechanism makes sense when you think about what GLP-1 agonism is doing in the brain. GLP-1 receptors are expressed in the reward and motivation circuits — the same pathways that govern appetite for food also play a role in cravings for alcohol and other reward-seeking behaviors. When those circuits are modulated, the compulsive quality of those urges decreases across the board.
This is consistent with what research on fasting and caloric restriction has shown — that appetite regulation at the central nervous system level has broader effects on reward-seeking behavior than just food. Andrew Huberman has discussed the neurotoxic effects of alcohol and the way the brain's reward circuitry responds to habitual drinking; semaglutide appears to be operating on similar neural substrate.
It's a secondary finding, not a primary indication. But it belongs in an honest accounting of what this drug does.
This is a clean factual list. If any of the following apply to you, semaglutide is not an appropriate option, and I will not prescribe it.
Side effects most commonly reported during dose titration include nausea, decreased appetite, and occasionally constipation or mild digestive changes. These typically improve as the body adjusts and are largely manageable with proper dose escalation.
I do not prescribe semaglutide to everyone who asks for it. I don't think it's the right tool for every patient, and I don't think weight loss should be the only reason to consider it.
The patients I'm most likely to recommend it for are dealing with insulin resistance, significant hormonal disruption, or a metabolic picture that hasn't responded to the foundational work — the cleanse, the dietary changes, the hormone support — despite genuine effort. These are patients for whom the underlying biology is working against them, and who need something that addresses that biology directly.
I also think about what happens after semaglutide. This drug works best when it's part of a broader effort to understand what drove the metabolic dysfunction in the first place — and to build habits, address nutrient deficiencies, and support hormonal balance so that when the patient eventually comes off the medication, the improvement holds. Using semaglutide as a standalone intervention without that context is a short-term solution to a long-term problem.
I was skeptical. I'm not anymore. What changed my mind wasn't the marketing — it was understanding the mechanism, and then watching what happened when I used it carefully and in context. The mechanism is real. The effects are real. And for patients who need it, the difference can be significant enough to change the trajectory of their health in a way that nothing before it was able to.
If you're curious whether it's right for you, reach out and we'll talk through it. I'd rather have a real conversation than have you piece this together from a social media thread.